{"id":"entecavir-pegylated-interferon-2b","safety":{"commonSideEffects":[{"rate":"40-70","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"10-30","effect":"Neutropenia"},{"rate":"5-15","effect":"Thrombocytopenia"},{"rate":"5-10","effect":"Depression/psychiatric effects"},{"rate":"20-40","effect":"Headache"},{"rate":"10-20","effect":"Injection site reactions"},{"rate":"<1","effect":"Lactic acidosis (entecavir-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Entecavir is a nucleoside reverse transcriptase inhibitor that directly blocks HBV replication by inhibiting the viral polymerase enzyme. Pegylated interferon α-2b is an immunomodulator that enhances innate and adaptive immune responses to clear HBV-infected hepatocytes. The combination aims to achieve superior viral suppression and potentially higher rates of HBeAg seroconversion compared to monotherapy.","oneSentence":"This combination uses entecavir to inhibit hepatitis B virus reverse transcriptase and pegylated interferon α-2b to enhance immune response against HBV-infected cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:29:19.644Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection"}]},"trialDetails":[{"nctId":"NCT07345624","phase":"PHASE4","title":"Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Qing-Lei Zeng","startDate":"2026-01-11","conditions":"Hepatitis B Virus Infection, Children, Chronic Hepatitis B","enrollment":80},{"nctId":"NCT07345611","phase":"PHASE4","title":"Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Qing-Lei Zeng","startDate":"2026-01-11","conditions":"Hepatitis B Virus Infection, Children, Chronic Hepatitis B","enrollment":60},{"nctId":"NCT07079150","phase":"","title":"Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study","status":"RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2025-01-01","conditions":"Hepatitis B, Chronic (CHB), Hepatitis B, Hepatitis B Virus (HBV)","enrollment":1500},{"nctId":"NCT06323681","phase":"NA","title":"Pegylated Interferon α in Previously Interferon-treated CHB（Leading Study）","status":"RECRUITING","sponsor":"Qing XIe","startDate":"2024-02-04","conditions":"Chronic Hepatitis b","enrollment":2016},{"nctId":"NCT05466565","phase":"","title":"Antiviral Therapy for Patients With Liver Cancer After Surgery","status":"RECRUITING","sponsor":"Xiangya Hospital of Central South University","startDate":"2021-12-01","conditions":"Hepatocellular Carcinoma","enrollment":360},{"nctId":"NCT03969017","phase":"PHASE2","title":"Combination Treatment of NAs and Peg IFN α-2b for Hepatitis B Related, Compensatory Cirrhosis Patients","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-06-17","conditions":"Cirrhosis of Liver Due to Hepatitis B (Disorder)","enrollment":84},{"nctId":"NCT01243281","phase":"NA","title":"Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Chulalongkorn University","startDate":"2011-03","conditions":"Chronic Hepatitis B","enrollment":126}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Runzhong®","PEGBING®"],"phase":"marketed","status":"active","brandName":"Entecavir + Pegylated interferon α-2b","genericName":"Entecavir + Pegylated interferon α-2b","companyName":"Qing-Lei Zeng","companyId":"qing-lei-zeng","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses entecavir to inhibit hepatitis B virus reverse transcriptase and pegylated interferon α-2b to enhance immune response against HBV-infected cells. Used for Chronic hepatitis B infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}